RxDoctor Payments Data

Lisa Aichholz

Nurse Practitioner · Bellevue, OHNPI 1285858241

Payments from drug & device makers

$3,570in general payments, 2019–2025

Across 214 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$864
  • GSK$213
  • Novo Nordisk$166
  • Pfizer$123
  • Amgen$102
  • plus $963 from 26 others

What the payments were for

  • Food & beverage$3,570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,570 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$34,151
Medicare patients
83
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$59,601
OzempicSemaglutide57$57,027
MounjaroTirzepatide27$36,375
JardianceEmpagliflozin31$31,548
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,076
TrulicityDulaglutide12$19,015
Spiriva RespimatTiotropium Bromide18$15,795
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$10,518
Breo ElliptaFluticasone/Vilanterol13$9,732
SymbicortBudesonide/Formoterol Fumarate26$7,840
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$5,639
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,466
Albuterol Sulfate HfaAlbuterol Sulfate113$3,367
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,358
Aripiprazole40$2,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$864$67,44191 claims
Novo NordiskOzempic$166$57,02757 claims
Lilly USA, LLCMounjaro, Trulicity$93$55,39039 claims
Boehringer IngelheimJardiance, Spiriva Respimat$54$47,34349 claims
GSKTrelegy Ellipta, Breo Ellipta$213$39,80753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Bellevue

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →